← Home
Research & Clinical Trials

Research that improves how patients are treated.

Dr. Mewawalla's work pairs clinical trials with real-world evidence and quality improvement so that advances in CAR T-cell therapy and bispecific antibodies reach patients safely.

Featured Research

Featured research.

Selected Publications

Selected publications.

Active Clinical Trials

Clinical trials.

Multiple myeloma and cellular therapy trials are available through the Allegheny Health Network Cancer Institute, where Dr. Mewawalla serves as principal or sub-investigator on more than 70 studies. Patients and referring physicians are welcome to ask about current options.

Selected trials as Principal Investigator

MajesTEC-7 (MMY3005)
Phase 3 · Teclistamab + daratumumab/lenalidomide and talquetamab + daratumumab/lenalidomide vs daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma · Janssen.
MagnetisMM-32 (C1071032)
Phase 3 · Elranatamab monotherapy vs EPd, PVd, or Kd in relapsed/refractory myeloma with prior anti-CD38 therapy · Pfizer.
DETER-SMM (EAA-173)
ECOG-ACRIN Phase 3 · Daratumumab plus lenalidomide vs lenalidomide in high-risk smoldering multiple myeloma.
ALPHA3 (ALLO-501A-202)
Phase 2 · Cemacabtagene ansegedleucel, an allogeneic anti-CD19 CAR T-cell therapy, in MRD-positive large B-cell lymphoma after first-line therapy · Allogene.
DALY II USA
Phase 2 · Autologous anti-CD20/anti-CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
LYL314-101
Phase 1/2 · LYL314, a CD19/CD20 dual-targeting CAR T-cell therapy, in aggressive B-cell non-Hodgkin lymphoma.
AMY2009 (Daratumumab-based therapy in AL amyloidosis)
Phase 2 multicohort study · Janssen.
Nipocalimab in warm autoimmune hemolytic anemia (M281)
Phase 2/3 randomized, double-blind, placebo-controlled study.
Implementation & Quality Improvement

Implementation and quality improvement.

21→7

CAR T-cell hospitalization

Helped lead a clinical workflow redesign associated with a reduction in institutional CAR T-cell hospitalization from approximately 21 to 7 days, an institutional quality-improvement outcome (not a published trial result).

Community

Bispecific ramp-up pathways

Standardized step-up dosing and monitoring pathways that support bispecific antibody administration closer to home.

FACT

Program growth & quality

Led growth, quality, and operational initiatives within an established FACT-accredited transplant and cellular therapy program, including expanding access to advanced cellular therapy services.

Research Collaborations

Research collaborations.

Active member of the U.S. Myeloma Innovations Research Collaborative (USMIRC), a multi-center group producing real-world evidence across leading U.S. cancer centers. Interested in a multi-center analysis, trial collaboration, or real-world data partnership in myeloma or cellular therapy? She welcomes the conversation.

Full Bibliography

Complete publication record.

Dr. Mewawalla has authored or co-authored 150+ scholarly works with 1,300+ citations. The full, continually updated list of publications is available on Google Scholar, PubMed, and ORCID.